Mitchell Mcleod Pugh & Williams Inc. Sells 395 Shares of Gilead Sciences, Inc. $GILD

Mitchell Mcleod Pugh & Williams Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% during the second quarter, according to its most recent filing with the SEC. The fund owned 9,138 shares of the biopharmaceutical company’s stock after selling 395 shares during the quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Gilead Sciences were worth $1,013,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Sagespring Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 28.5% in the 2nd quarter. Sagespring Wealth Partners LLC now owns 17,351 shares of the biopharmaceutical company’s stock worth $1,924,000 after buying an additional 3,848 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of Gilead Sciences by 44.7% in the 2nd quarter. TD Asset Management Inc now owns 3,420,676 shares of the biopharmaceutical company’s stock worth $379,250,000 after buying an additional 1,056,474 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Gilead Sciences by 3.1% in the 2nd quarter. Revolve Wealth Partners LLC now owns 3,595 shares of the biopharmaceutical company’s stock worth $399,000 after buying an additional 108 shares during the last quarter. Cornerstone Wealth Group LLC boosted its holdings in shares of Gilead Sciences by 20.1% in the 2nd quarter. Cornerstone Wealth Group LLC now owns 2,822 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 472 shares during the last quarter. Finally, NorthRock Partners LLC boosted its holdings in shares of Gilead Sciences by 11.1% in the 2nd quarter. NorthRock Partners LLC now owns 12,922 shares of the biopharmaceutical company’s stock worth $1,433,000 after buying an additional 1,290 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,000 shares of company stock worth $7,632,100. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.2%

GILD stock opened at $118.48 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The company’s 50 day moving average is $114.84 and its 200 day moving average is $110.35. The stock has a market cap of $147.01 billion, a price-to-earnings ratio of 23.60, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 1-year low of $84.80 and a 1-year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s dividend payout ratio is 62.95%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a report on Friday, July 25th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, UBS Group upped their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $118.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.